|Trade names||Xenazine, Xentra, Nitoman, others|
|AHFS/Drugs.com||Consumer Drug Information|
|By mouth (tablets)|
|Bioavailability||Low, extensive first pass effect|
|Elimination half-life||10 hours parent compound (2 to 8 hours active metabolites)|
|Excretion||Renal (~75%) and fecal (7–16%)|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||317.429 g·mol−1|
|3D model (JSmol)|
Tetrabenazine is a drug for the symptomatic treatment of hyperkinetic movement disorders. It is sold under the brand names Nitoman and Xenazine among others. On August 15, 2008, the U.S. Food and Drug Administration approved the use of tetrabenazine to treat chorea associated with Huntington's disease. Although other drugs had been used "off label," tetrabenazine was the first approved treatment for Huntington's disease in the U.S. The compound has been known since the 1950s.
- Huntington's disease – specifically, the chorea associated with it
- Tourette syndrome and other tic disorders
- Tardive dyskinesia, a serious and sometimes irreversible side effect of long-term use of many antipsychotics, mainly typical antipsychotics
- Hemiballismus, spontaneous flinging limb movements due to contra-lateral subthalamic nucleus damage
The most common adverse reactions, which have occurred in at least 10% of subjects in studies and at least 5% greater than in subjects who received placebo, have been: sedation or somnolence, fatigue, insomnia, depression, suicidal thoughts, akathisia, anxiety and nausea.
- Increases the risk of depression and suicidal thoughts and behavior in patients with Huntington's disease
- Balance risks of depression and suicidality with the clinical need for control of chorea when considering the use of tetrabenazine
- Monitor patients for emergence or worsening of depression, suicidality or unusual changes in behavior
- Inform patients, caregivers and families of the risk of depression and suicidality and instruct to report behaviours of concern promptly to the treating physician
- Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation
- Tetrabenazine is contraindicated in patients who are actively suicidal and in patients with untreated or inadequately treated depression
The precise mechanism of action of tetrabenazine is unknown. Its anti-chorea effect is believed to be due to a reversible depletion of monoamines such as dopamine, serotonin, norepinephrine, and histamine from nerve terminals. Tetrabenazine reversibly inhibits vesicular monoamine transporter 2, resulting in decreased uptake of monoamines into synaptic vesicles, as well as depletion of monoamine storage.
- Yero, T.; Rey, J. A. (2008). "Tetrabenazine (Xenazine), An FDA-Approved Treatment Option For Huntington's Disease". P & T: A Peer-Reviewed Journal for Formulary Management. 33 (12): 690–694. PMC 2730806. PMID 19750050.
- "Xenazine (tetrabenazine) Tablets, for Oral Use. Full Prescribing Information. Revised: 6/2015" (PDF). H. Lundbeck A/S. Retrieved 9 December 2015.
- 1st US drug for Huntington's disease wins approval[dead link]
- Jankovic J, Beach J (1997). "Long-term effects of tetrabenazine in hyperkinetic movement disorders". Neurology. 48 (2): 358–62. doi:10.1212/wnl.48.2.358. PMID 9040721. S2CID 33577525.
- Kenney C, Hunter C, Jankovic J (January 2007). "Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders". Movement Disorders. 22 (2): 193–7. doi:10.1002/mds.21222. PMID 17133512. S2CID 22001960.
- Ondo WG, Hanna PA, Jankovic J (August 1999). "Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol". American Journal of Psychiatry. 156 (8): 1279–81. doi:10.1176/ajp.156.8.1279. PMID 10450276. S2CID 40131860.
- SMITH ME (March 1960). "Clinical comparison of tetrabenazine (Ro 1-9569), reserpine and placebo in chronic schizophrenics". Dis Nerv Syst. 21 (3 Suppl): 120–3. PMID 13832091.
- SACERDOTI G (1960). "First clinical experiences with tetrabenazine" [First clinical experiences with tetrabenazine]. Rass Studi Psichiatr (in Italian). 49: 450–60. PMID 13745210.
- Schmitt, W. (July 1960). "Zur Pharmakotherapie der Psychosen: Klinische Untersuchungen mit Tetrabenazin" [On the pharmacotherapy of psychoses: clinical research on tetrabenazine]. Psychiatr Neurol (Basel) (in German). 140: 23–9. doi:10.1159/000131224. PMID 13748124.
- Ashcroft, G. W.; MacDougall, Elizabeth J.; Barker, P. A. (March 1961). "A comparison of tetrabenazine and chlorpromazine in chronic schizophrenia". J Ment Sci. 107 (447): 287–93. doi:10.1192/bjp.107.447.287. PMID 13684728.
- BURCKARD E; MEDHAOUI M; MONTIGNEAUX P; PFITZENMEYER J; PFITZENMEYER H; SCHAETZEL JC; SINGER L; GEISSMANN P (January 1962). "Clinical, biological and electroencephalographic study of the action of tetrabenazine (Ro 956) in various chronic psychoses" [Clinical, biological and electroencephalographic study of the action of tetrabenazine (Ro 956) in various chronic psychoses]. Ann Med Psychol (Paris) (in French). 120 (1): 115–9. PMID 13874731.
- KAMMERER T; SINGER L; GEISSMANN P; WETTA JM (January 1962). "Use of a new neuroleptic: Tetrabenazine. Clinical, biological and electroencephalographic results" [Use of a new neuroleptic: tetrabenazine. Clinical, biological and electroencephalographic results]. Ann Med Psychol (Paris) (in French). 120 (1): 106–15. PMID 14453492.
- LINGJAERDE O (1963). "Tetrabenazine (Nitoman) in the Treatment of Psychoses. With a Discussion on the Central Mode of Action of Tetrabenazine and Reserpine". Acta Psychiatr Scand. 39: SUPPL170:1–109. PMID 14081399.
- Matsumoto Y, Totsuka S, Kato M, Inoue M, Okagami K (July 1966). "[Therapy of schizophrenia with tetrabenazine]". Nihon Rinsho (in Japanese). 24 (7): 1360–4. PMID 6007641.
- Malik A, Balkoski V (November 2007). "Neurotransmitter depleter tetrabenazine; potential candidate for schizophrenia treatment?". Schizophr Res. 96 (1–3): 267–8. doi:10.1016/j.schres.2007.07.010. PMID 17683910. S2CID 39312847.
- Remington G, Kapur S, Foussias G, Agid O, Mann S, Borlido C, Richards S, Javaid N (February 2012). "Tetrabenazine augmentation in treatment-resistant schizophrenia: a 12-week, double-blind, placebo-controlled trial". J Clin Psychopharmacol. 32 (1): 95–9. doi:10.1097/JCP.0b013e31823f913e. PMID 22198452. S2CID 2649261.
- Kaur N, Kumar P, Jamwal S, Deshmukh R, Gauttam V (September 2016). "Tetrabenazine: Spotlight on Drug Review". Ann Neurosci. 23 (3): 176–185. doi:10.1159/000449184. PMC 5043267. PMID 27721587.